Pacer Advisors
RCUS icon

Pacer Advisors’s Arcus Biosciences RCUS Stock Holding History

Pacer Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Buy
+1,198
New +$29.6K ﹤0.01% 2108
2024
Q3 		– Sell
-545
Closed -$8.3K – 2668
2024
Q2 		$8.3K Sell
545
-1,034
-65% -$16.7K ﹤0.01% 3581
2024
Q1 		$29.8K Buy
+1,579
New +$27.3K ﹤0.01% 3359
2021
Q2 		– Sell
-2,145
Closed -$60K – 1529
2021
Q1 		$60K Buy
2,145
+66
+3% +$2.3K ﹤0.01% 1419
2020
Q4 		$54K Buy
2,079
+338
+19% +$8.18K ﹤0.01% 1410
2020
Q3 		$30K Buy
+1,741
New +$38.9K ﹤0.01% 1335

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Pacer Advisors's RCUS Position: Q2 2026 in Review

Pacer Advisors opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 1,198 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #2108 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in RCUS as recently as Q2 2024.

Pacer Advisors first reported a position in RCUS in Q3 2020 and has held it in 6 quarters since. The position peaked at $60K in Q1 2021. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Pacer Advisors held 1,198 shares of Arcus Biosciences worth $37K as of Q2 2026.
  • Arcus Biosciences was a new Pacer Advisors position in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2108 holding.
  • Pacer Advisors first reported a position in Arcus Biosciences in Q3 2020 and has held it in 6 quarters since.
  • Pacer Advisors's Arcus Biosciences position peaked at $60K in Q1 2021.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.